Price tag for a questionable Alzheimer’s treatment: $109,000 per patient, per year. Unclear yet: For how many years?

By SharpBrains | August 2, 2023

The real costs of the new Alzheimer’s drug, Leqem­bi — and why tax­pay­ers will foot much of the bill (CBS News): The first drug pur­port­ing to slow the advance of Alzheimer’s dis­ease is like­ly to cost the U.S. health care sys­tem bil­lions annu­al­ly even as it remains out of reach for many of the low­er-income seniors…

Read More

Should doctors prescribe Leqembi (lecanemab) to women with early Alzheimer’s Disease? The evidence-based answer is probably No

By SharpBrains | June 28, 2023

Wel­come to a new edi­tion of Sharp­Brains e‑newsletter, fea­tur­ing this time a range of inter­ven­tions for brain/ cognitive/ men­tal health plus a few brain teasers to test our per­cep­tion and cog­ni­tive skills. #1. Should doc­tors pre­scribe lecanemab (Leqem­bi) to women? The answer, giv­en avail­able evi­dence, is prob­a­bly No Huge (and most­ly over­looked) red flag regard­ing newly…

Read More

Study finds ADHD is associated with dementia

By SharpBrains | September 16, 2021

Multi­gen­er­a­tional Study Finds Links Between ADHD, Demen­tia Risk (Health Day): Atten­­tion-deficit/hy­per­ac­­tiv­i­­ty dis­or­der (ADHD) appears to be some­how linked to risk of demen­tia and Alzheimer’s dis­ease, a new multi­gen­er­a­tional study has found. Par­ents and grand­par­ents of peo­ple with ADHD have a high­er risk of Alzheimer’s and demen­tia than peo­ple with no ADHD in their fam­i­ly, Swedish researchers…

Read More

On cognitive reframing and biases, stress, mental health tech, Aduhelm backlash, Britney Spears, and more

By SharpBrains | August 31, 2021

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing this time nine sci­en­tif­ic reports and indus­try devel­op­ments to help pro­mote life­long brain and men­tal health. #1. To low­er stress lev­els and improve prob­lem-solv­ing, prac­tice cog­ni­tive refram­ing instead of vent­ing “… vent­ing like­ly doesn’t soothe anger as much as aug­ment it. That’s because encour­ag­ing peo­ple to…

Read More

Veterans Affairs won’t cover Biogen’s new “Alzheimer’s drug” given concerns over safety and lack of evidence

By SharpBrains | August 16, 2021

VA Health Sys­tem Won’t Cov­er Biogen’s Alzheimer’s Drug (The Wall Street Jour­nal): The Depart­ment of Vet­er­ans Affairs won’t cov­er Bio­gen Inc.’s new Alzheimer’s drug, the lat­est rebuke of the con­tro­ver­sial treat­ment since it was approved ear­li­er this sum­mer. The VA decid­ed not add the drug, called Aduhelm, to its for­mu­la­ry list of avail­able med­i­cines because…

Read More